Optimer Pharmaceuticals (Nasdaq: OPTR) is expected to report Q3 earnings on Nov. 1. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Optimer Pharmaceuticals's revenues will grow 59.7% and EPS will remain in the red.

The average estimate for revenue is $17.6 million. On the bottom line, the average EPS estimate is -$0.63.

Revenue details
 Last quarter, Optimer Pharmaceuticals recorded revenue of $49.8 million. GAAP reported sales were much higher than the prior-year quarter's $.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, EPS came in at -$0.01. GAAP EPS were -$0.01 for Q2 against -$0.52 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 68.7%, 3,088,120 basis points better than the prior-year quarter. Operating margin was 0.7%, 7,515,300 basis points better than the prior-year quarter. Net margin was -0.6%, 7,281,060 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $100.8 million. The average EPS estimate is -$1.41.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 108 members out of 142 rating the stock outperform, and 34 members rating it underperform. Among 47 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 33 give Optimer Pharmaceuticals a green thumbs-up, and 14 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Optimer Pharmaceuticals is outperform, with an average price target of $19.50.